Status:

TERMINATED

MDR - Longevity IT Oblique and Offset Liners

Lead Sponsor:

Zimmer Biomet

Conditions:

Non-inflammatory Degenerative Joint Disease (NIDJD)

Avascular Necrosis

Eligibility:

All Genders

18+ years

Brief Summary

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Longevity IT Oblique ...

Detailed Description

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Longevity IT Oblique ...

Eligibility Criteria

Inclusion

  • Study devices must have been implanted following the appropriate surgical technique and IFU
  • Patient must be 18 years of age or older
  • Patient must be willing and able to sign or verbally consent using the IRB approved informed consent
  • Patient must have undergone primary or revision hip arthroplasty with the Longevity IT Oblique and/or Offset liners according to a cleared indication, which includes the following:
  • Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis, protrusio acetabuli, traumatic arthritis, slipped capital, epiphysis, fused hip, fracture of the pelvis, and diastrophic variant
  • Revision where other devices or treatments have failed
  • Patient must have reached full skeletal maturity

Exclusion

  • Off-label use of study devices
  • Osteoradionecrosis
  • Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation
  • Systemic or local infection
  • Uncooperative patient or patient with neurologic disorders who is incapable of following directions
  • Patient is known to be pregnant or nursing
  • Patient is a prisoner
  • Patient is a known alcohol or drug abuser
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent

Key Trial Info

Start Date :

August 30 2023

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 7 2024

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT05980234

Start Date

August 30 2023

End Date

November 7 2024

Last Update

December 27 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rothman Institute

Philadelphia, Pennsylvania, United States, 19107